



UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 5 2001

FEB 5 2001

Commissioner for Patents  
United States Patent and Trademark Office  
Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

David T. Read  
Acting Director Regulatory Policy Staff, CDER  
Food and Drug Administration  
1451 Rockville Pike, HFD-7  
Rockville, MD 20852

#19

Dear Mr. Read:

The attached application for patent term extension of U.S. Patent No. 4,868,112, was filed on May 4, 2000, under 35 U.S.C. § 156.

The assistance of your Office is requested in confirming that the product identified in the application, ReFacto®, has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within sixty days after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Karin Tyson  
Karin Tyson  
Senior Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner for Patent Examination Policy

cc: Stephen P. O'Connor  
Finnegan Henderson Farabow Garrett & Dunner  
1300 I Street NW  
Washington DC 20005-3315